Long-term Follow-up Study for Azer-Cel Treatment
Part of Immune system & allergy clinical trials.
This study tracks the long-term safety and effects of azer-cel, a cell-based cancer treatment, in people who previously received it in an earlier trial. Researchers want to understand how the treatment works over time and ensure your ongoing health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received at least one dose of azer-cel in the earlier TG-Azercel-101 study
- You must sign an informed consent form (a document confirming you understand the study and agree to participate)
- You must be willing and able to attend study visits and follow the study schedule as planned
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational cell therapy called Azer-cel in people with certain autoimmune diseases that affect the nerves or muscles. It aims to see if the treatment is safe and can help reduce symptoms by targeting the immune system.
This study checks how people do over a longer period after receiving azer-cel in an Imugene trial. It helps doctors understand long-term safety and health outcomes, even if you are feeling well now.
This trial is for people who have already received a cell or gene therapy in another AstraZeneca study. It simply checks in on your health over time after that treatment.
This Phase 1 study tests the safety and best dose of a CD19 CAR T cell therapy (azer-cel) in people whose B-cell blood cancer has returned or did not respond to treatment. It may help people with relapsed/refractory B-ALL or certain aggressive or large B-cell lymphomas, including after or before prior CAR T treatment.
This trial tests if a new medication, AZD0120, is safe for people with autoimmune diseases. It aims to help patients by targeting the immune system.
This is a long-term follow-up study for people who have already received gene-modified T-cell therapy. It observes your health over time to see how well the treatment worked and any long-term effects.
Hear when a new B-cell Mediated Autoimmune Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.